Contenu de la page.

Références pour les maladies du sein

Thématique : Approche de l'aisselle

  • Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-75. Epub 2011/02/10. doi: 10.1001/jama.2011.90. PubMed PMID: 21304082; PubMed Central PMCID: PMCPMC5389857.

  • Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305. Epub 2013/03/16. doi: 10.1016/S1470-2045(13)70035-4. PubMed PMID: 23491275; PubMed Central PMCID: PMCPMC3935346.

  • Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303-10. Epub 2014/12/03. doi: 10.1016/S1470-2045(14)70460-7. PubMed PMID: 25439688; PubMed Central PMCID: PMCPMC4291166.

  • Gooch J, King TA, Eaton A, Dengel L, Stempel M, Corben AD, et al. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer. Ann Surg Oncol. 2014;21(9):2897-903. Epub 2014/04/30. doi: 10.1245/s10434-014-3752-0. PubMed PMID: 24777858; PubMed Central PMCID: PMCPMC4346337.

  • Geng C, Chen X, Pan X, Li J. The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(9):e0162605. Epub 2016/09/09. doi: 10.1371/journal.pone.0162605. PubMed PMID: 27606623; PubMed Central PMCID: PMCPMC5015960.

  • Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-61. Epub 2013/10/09. doi: 10.1001/jama.2013.278932. PubMed PMID: 24101169; PubMed Central PMCID: PMCPMC4075763.

  • Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258-64. Epub 2014/12/03. doi: 10.1200/JCO.2014.55.7827. PubMed PMID: 25452445.

Thématique : Obstétrique 

  • Royal College of Obstetricians & Gynaecologists. Pregnancy and Breast Cancer. Green-top Guideline No. 12. March 2011. Accédé le 2021-02-01.

  • American College of Radiology. ACR Appropriateness Criteria. Breast Imaging of Pregnant and Lactating Women. 2018. Accédé 2021-02-01.

  • Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010;46(18):3158-68. Epub 2010/10/12. doi: 10.1016/j.ejca.2010.09.010. PubMed PMID: 20932740.

  • Barnes DM, Newman LA. Pregnancy-associated breast cancer: a literature review. Surg Clin North Am. 2007;87(2):417-30, x. Epub 2007/05/15. doi: 10.1016/j.suc.2007.01.008. PubMed PMID: 17498535.

  • Bure LA, Azoulay L, Benjamin A, Abenhaim HA. Pregnancy-associated breast cancer: a review for the obstetrical care provider. J Obstet Gynaecol Can. 2011;33(4):330-7. Epub 2011/04/20. doi: 10.1016/s1701-2163(16)34850-2. PubMed PMID: 21501537.

  • Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010;16(1):76-82. Epub 2010/02/19. doi: 10.1097/PPO.0b013e3181ce46f9. PubMed PMID: 20164696.

  • Cardonick E, Gilmandyar D, Somer RA. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol. 2012;120(6):1267-72. Epub 2012/11/22. doi: http://10.1097/AOG.0b013e31826c32d9

  • 10.1097/aog.0b013e31826c32d9. PubMed PMID: 23168749.

  • Johansson ALV, Andersson TM, Hsieh CC, Jirstrom K, Cnattingius S, Fredriksson I, et al. Tumor characteristics and prognosis in women with pregnancy-associated breast cancer. Int J Cancer. 2018;142(7):1343-54. Epub 2017/11/24. doi: 10.1002/ijc.31174. PubMed PMID: 29168177.

  • Lee YY, Roberts CL, Dobbins T, Stavrou E, Black K, Morris J, et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study. BJOG. 2012;119(13):1572-82. Epub 2012/09/06. doi: 10.1111/j.1471-0528.2012.03475.x. PubMed PMID: 22947229; PubMed Central PMCID: PMCPMC3533794.

  • Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13(9):887-96. Epub 2012/08/21. doi: 10.1016/S1470-2045(12)70261-9. PubMed PMID: 22902483.

  • Macdonald HR. Pregnancy associated breast cancer. Breast J. 2020;26(1):81-5. Epub 2020/01/17. doi: 10.1111/tbj.13714. PubMed PMID: 31943583.

  • O'Lauglin A, So S, Fleischer L, Akoto S, Cardonick E. Safety of Taxane Chemotherapy in Breast Cancer During Pregnancy. Obstet Gynecol. 2019;133(Suppl):169-70.

  • Poggio F, Tagliamento M, Pirrone C, Soldato D, Conte B, Molinelli C, et al. Update on the Management of Breast Cancer during Pregnancy. Cancers (Basel). 2020;12(12). Epub 2020/12/09. doi: 10.3390/cancers12123616. PubMed PMID: 33287242; PubMed Central PMCID: PMCPMC7761659.

  • Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA. 2016;316(9):952-61. Epub 2016/09/07. doi: 10.1001/jama.2016.12126. PubMed PMID: 27599330.

  • Reyes E, Xercavins N, Saura C, Espinosa-Bravo M, Gil-Moreno A, Cordoba O. Breast cancer during pregnancy: matched study of diagnostic approach, tumor characteristics, and prognostic factors. Tumori. 2020;106(5):378-87. Epub 2020/07/07. doi: 10.1177/0300891620925158. PubMed PMID: 32623975.

  • Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol. 2005;23(18):4192-7. Epub 2005/06/18. doi: 10.1200/JCO.2005.03.038. PubMed PMID: 15961766.

  • Rojas KE, Bilbro N, Manasseh DM, Borgen PI. A Review of Pregnancy-Associated Breast Cancer: Diagnosis, Local and Systemic Treatment, and Prognosis. J Womens Health (Larchmt). 2019;28(6):778-84. Epub 2018/11/28. doi: 10.1089/jwh.2018.7264. PubMed PMID: 30481102.

  • Vallurupalli M, Partridge AH, Mayer EL. Treatment of Breast Cancer During Pregnancy. Curr Breast Cancer Rep. 2017;9:195-201. doi:

Thématique : Chimiothérapie néoadjuvante triple-négatif

  • Chen X, Ye G, Zhang C, Li X, Chen Y, Xie X, et al. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. Breast Cancer Res Treat. 2013;142(3):549-58. Epub 2013/12/03. doi: 10.1007/s10549-013-2790-9 10.1007/s10549-013-2761-1. PubMed PMID: 24292815.
  • Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Hojris I, et al. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. J Clin Oncol. 2017;35(23):2639-46. Epub 2017/07/01. doi: 10.1200/JCO.2017.72.3494. PubMed PMID: 28661759.

  • Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, et al. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J Clin Oncol. 2019;37(10):799-808. Epub 2019/02/21. doi: 10.1200/JCO.18.00028. PubMed PMID: 30785826.

  • Schmid P, Cortes J, Dent R, Pusztal L, McArthur HL, Kuemmel S, et al. 1812 - KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Ann Oncol. 2019;30(Suppl_5):v851-v934.

  • Poggio F, Bruzzone M, Ceppi M, Ponde NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497-508. Epub 2018/06/07. doi: 10.1093/annonc/mdy127. PubMed PMID: 29873695.

  • Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747-56. Epub 2014/05/06. doi: 10.1016/S1470-2045(14)70160-3. PubMed PMID: 24794243.

  • Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497-509. Epub 2018/03/05. doi: 10.1016/S1470-2045(18)30111-6. PubMed PMID: 29501363.

  • Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13-21. Epub 2014/08/06. doi: 10.1200/JCO.2014.57.0572. PubMed PMID: 25092775; PubMed Central PMCID: PMCPMC4268249.

  • Early Breast Cancer Trialists' Collaborative G. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393(10179):1440-52. Epub 2019/02/12. doi: 10.1016/S0140-6736(18)33137-4. PubMed PMID: 30739743; PubMed Central PMCID: PMCPMC6451189.

  • Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol. 2014;15(2):201-12. Epub 2013/12/24. doi: 10.1016/S1470-2045(13)70554-0. PubMed PMID: 24360787.


Dernière révision du contenu : le 4 août 2021

Signaler une erreur ou émettre un commentaire